US FDA clears diabetes drug for treatment of obesity
The US Food and Drug Administration (FDA) has approved diabetes drug Liraglutide (Saxenda, Novo Nordisk) for the treatment of obesity. Liraglutide, was first approved in 2010 as a treatment for type 2